Drug discontinuation: Imipenem and Cilastatin Injection (PRIMAXIN IV)
FDA lists 1 presentation as To Be Discontinued. Companies: Merck Sharp & Dohme Corp..
- Published by source
- 2026-01-08
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Merck Sharp & Dohme Corp.
- Products
- Imipenem and Cilastatin Injection PRIMAXIN IV
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- To be discontinued approximately 11/30/2026
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-01-08
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #954 | new | 2026-10-22 | 274d8df6ead5…106b65 | d143000fb13e…27780b |
Chain head: #1076 8ad5adc30b9b…88ce20